Olanzapine is under clinical development by MedinCell and currently in Phase III for Schizophrenia. According to GlobalData, Phase III drugs for Schizophrenia have a 68% phase transition success rate (PTSR) indication benchmark for progressing into Pre-Registration. GlobalData’s report assesses how Olanzapine’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Olanzapine overview
olanzapine (MDC-TJK) is under development for the treatment of schizophrenia. It is administered by subcutaneous route. It acts by targeting serotonin receptor 2A and D2 dopamine receptor. It is developed as long-acting PEGylated formulation based on BEPO technology. BEPO consists of copolymers and a biocompatible solvent, where the active pharmaceutical ingredients are suspended.
MedinCell overview
MedinCell is a developer of long-acting injectable products in various therapeutic areas. It develops and commercializes BEPO, a technology based on custom proprietary copolymers and a biocompatible solvent for long acting injectables. The company’s BEPO provides a controlled release of therapeutic molecules and can be used to improve the treatment of a variety of chronic diseases or short-term illnesses. MedinCell offers peptides and proteins delivery services. MedinCell offers products for various indications including schizophrenia, pain and inflammation, depression, anaesthesia, organ transplant, and others. The company works for profit and non-profit projects and collaborates with partners including pharma, physicians, biotech firms, academics and foundations. MedinCell is headquartered in Jacou, France.
For a complete picture of Olanzapine’s drug-specific PTSR and LoA scores, buy the report here.
Premium Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.